ERBB2 and esophageal squamous cell carcinoma: Several novel immune and targeted drugs for advanced ESCC therapy have been approved by the U.S. Food and Drug Administration (FDA), such as programmed cell death protein 1 (PD-1) inhibitors and human epidermal growth factor receptor 2 (Her-2) inhibitors, but the survival rate in advanced patients remain low3, 4.